Pioneering composite programmable medicines to advance drug development.
We are biotechnology and engineering experts, building advanced medicines from the ground up with precision and innovation.
Together, we use cutting edge technologies including programmable DNA nanofabrication and AI-supported molecular design to make drugs for difficult medical challenges.
Our goal? Enable impactful proactive AND rapid response advanced therapy development.
A Story of Progress
CPTx is pioneering composite programmable therapeutics to change the paradigm of advanced medicine production.
Founded in 2021 in Munich, Germany, we set out to translate more than 15 years of research at the Technical University of Munich into novel therapeutics. Merging science and engineering, we leverage composite therapeutic DNA-based nanofabrication for faster and safer drug development across modalities. Working with our technology facilitates precise placement and polyvalent presentation of a variety of drug molecules in unique nanostructures that enable highly targeted delivery.
Our leadership team includes high profile academic and industry experts, enabling us to address disease challenges across genetic, infectious, and autoimmune diseases fields.
15+
Years of Research10+
Nature & Science Papers Published100+
Research Papers Authored
Leadership Team
Forgoing a career as a pilot, Hendrik decided to pursue his passion for science at the Technical University of Munich and then at Harvard Medical School and the Dana-Farber Cancer Institute.
While gaining tenure as a full professor at TUM, he focused exclusively on advancing programmable DNA nanofabrication for over 15 years. Committed to transforming theoretical ideas into practical applications, Hendrik founded and leads CPTx, a company that aims to revolutionize medicine with bionanotechnology.
Grant Boldt, our chief operations officer, holds a Ph.D. in Chemical Biology from Scripps Research Institute, fueling his fast-paced career in the biopharma industry.
With senior executive roles as Vice President and P&L owner at biotechs including Sigma Aldrich, Lonza, and Avantor, Grant has driven fast business growth and shaped the trajectory of global corporations.
His motto is difficilia quae pulchra - in difficulty lies beauty. Grant has a passion for complexity and his adventurous spirit finds motorcycle racing and company building equally compelling.
Meet Christian Sigl: the trailblazing CTO of CPTx and former volunteer firefighter turned DNA nanoengineer. His love for geometric patterns like icosahedrons and pentagons is at the heart of his innovative approach to biotech. Christian's groundbreaking doctoral work was crucial in developing CPTx’s first therapeutic breakthrough—the antiviral nanochassis.
At CPTx, Christian combines his blend of emergency management skills and biophysical insight to lead pioneering technological advancements for precision-based therapies.
Stefan is a seasoned executive with extensive experience in biopharma, life science tools, and specialty chemicals. He was the Chairman and CEO at Merck KGaA, where he spearheaded the company's successful transformation into a leading science and technology firm. Under his leadership, Merck introduced two blockbuster products in neuroscience and oncology.
Following his seven-year tenure at Merck, Stefan became chairman of UCB and AiCuris, and he currently works as a partner at the private equity firm Armira. His earlier career included senior roles at Merck & Co. (MSD), including President of Emerging Markets and President of Europe/Middle East/Africa, after starting in R&D at MSD and working in research at the International Atomic Energy Agency. Stefan earned a doctorate (DVM) from the University of Munich.
Pioneering in Place
Our state-of-the-art production facility in Munich is at the forefront of nanofabrication technology.
We have 3,600m2 of upstream and downstream parallel processing capacity with exceptional scalability for the footprint. Good Manufacturing Practice (GMP) validation is in process.
Owned supply chain
Supported By
